The potent anti-inflammatory effects of SIRT1, mediated through transcriptional and epigenetic mechanisms, suggest that modulation of SIRT1 activity could be exploited as a therapeutic approach to control vascular inflammation in PAH. The gene discussed is SIRT1; the disease is pulmonary arterial hypertension.